Metoprolol Sandoz (Metoprolol Succinate)

Metoprolol succinate selectively blocks β1‑adrenergic receptors in the heart. By inhibiting sympathetic stimulation, it reduces heart rate, myocardial contractility, and cardiac output, which together lower arterial pressure and decrease the heart's oxygen demand.

The appropriate dose of Metoprolol Sandoz is determined by the prescribing clinician based on the patient’s medical condition, response to therapy and any co‑existing health issues. Dosage adjustments are made during treatment to achieve optimal blood pressure or heart‑failure control.

Safety data for metoprolol succinate in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoprolol succinate is a cardio‑selective β1‑blocker, offering a favorable profile for patients with hypertension, angina or heart failure. Compared with non‑selective beta blockers, it has less impact on bronchial β2 receptors, making it a preferred option for patients with mild respiratory disease.

Metoprolol Sandoz should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain its stability and potency throughout its shelf life.

Metoprolol Sandoz is taken orally, usually as a whole tablet swallowed with water. It may be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any dose‑timing considerations.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in susceptible individuals, and worsening of heart‑failure symptoms. Patients should seek immediate medical attention if they experience fainting, rapid weight gain, severe shortness of breath or chest pain.

Metoprolol Sandoz is contraindicated in patients with known hypersensitivity to metoprolol or any excipients, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and individuals in cardiogenic shock. Caution is also advised for patients with severe asthma or chronic obstructive pulmonary disease.